Comprehensive coverage

"Andromeda Biotech" announced that a medicinal substance for the treatment of type 1 diabetes met the goals in a clinical trial

DiaPep277 was invented by Prof. Yaron Cohen and members of his research group at the Weizmann Institute of Science. It is a peptide (short protein) consisting of 24 amino acids, which is a partial segment of the human protein called Hsp60, which is responsible for the body's handling of extreme heat stress

Prof. Yaron Cohen, Weizmann Institute
Prof. Yaron Cohen, Weizmann Institute

"Andromeda Biotech" announced that a medicinal substance for the treatment of type 1 diabetes,
Developed by Prof. Yaron Cohen at the Weizmann Institute of Science, met primary and secondary objectives in clinical trials in the third phase

The trial was randomized, controlled, double-blind and multicenter. The trial included 457 patients aged 16-45, who were diagnosed with type 1 diabetes near the start of treatment. The trial was conducted in approximately 40 medical centers in Europe, Israel and South Africa.

The patients in the experiment were randomly assigned to two groups: the treatment group that was given the drug (DiaPep277) via a subcutaneous injection once every three months, for two years, and a control group that was treated with a placebo in the same way. In addition, all patients were treated with insulin according to blood glucose levels.

DiaPep277 was invented by Prof. Yaron Cohen and members of his research group at the Weizmann Institute of Science. It is a unique peptide (short protein) consisting of 24 amino acids, which is a partial segment of the human protein called Hsp60, which is responsible for the body's handling of extreme heat stress. The peptide works by regulating the immune system, thus preventing the destruction of the pancreatic cells that secrete insulin, and preserves their natural activity. Treating patients with type 1 diabetes using DiaPep277 may have several medical benefits, including slowing the rate of disease progression, improving metabolic control, reducing the dose of insulin that the patient needs to inject daily, and reducing the complications of diabetes.

In the experiment, the ability to secrete insulin by the pancreas was tested. The initial data analysis shows that patients who were treated with the drug for at least a year, maintained a significantly better ability of the pancreas to secrete insulin compared to the control group.

In terms of the safety profile, no significant differences were found in the number of side effects between the treatment group and the control group. Additional efficacy and safety data are being collected and tested, and will be presented in the final report of the trial which will be completed in a few months.

"Andromeda Biotech" continues with another experiment, with the aim of verifying the results. Recruitment of patients for this trial is expected to be completed in the second quarter of 2012.
The development team of "Andromeda Biotech" clarifies that the development phase of the drug has not yet ended, and that there is no certainty that the drug will reach marketing on a commercial basis.

2 תגובות

Leave a Reply

Email will not be published. Required fields are marked *

This site uses Akismat to prevent spam messages. Click here to learn how your response data is processed.